Who are EL219's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): standard dose of HCQ, Imiquimod and Interferon alpha, Aldara (imiquimod) cream, 5%, Imiquimod 3.75% Cream, Imiquimod 5% Topical Cream, Imiquimod 5% Cream.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/el219.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

EL219 — Competitive Intelligence Brief

EL219 (EL219) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: TLR7 agonist. Area: Oncology.

phase 2 TLR7 agonist TLR7 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

EL219 (EL219) — Elion Therapeutics, Inc.. EL219 is an immunostimulatory agent designed to activate innate immune responses against cancer.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
EL219 TARGET	EL219	Elion Therapeutics, Inc.	phase 2	TLR7 agonist	TLR7
standard dose of HCQ	standard dose of HCQ	University of Sao Paulo General Hospital	marketed	Antimalarial immunosuppressant	Toll-like receptors (TLR7, TLR9); phospholipase C
Imiquimod and Interferon alpha	Imiquimod and Interferon alpha	The University of Texas Health Science Center, Houston	marketed	Immunostimulant combination	TLR7/8 (imiquimod); Interferon-alpha receptor (interferon alpha)
Aldara (imiquimod) cream, 5%	Aldara (imiquimod) cream, 5%	Graceway Pharmaceuticals, LLC	marketed	TLR7 agonist	TLR7 (Toll-like receptor 7)
Imiquimod 3.75% Cream	Imiquimod 3.75% Cream	Medical University of Graz	marketed	TLR7 agonist	TLR7 (Toll-like receptor 7)
Imiquimod 5% Topical Cream	Imiquimod 5% Topical Cream	University of Michigan	marketed	Toll-like receptor 7 (TLR7) agonist	TLR7
Imiquimod 5% Cream	Imiquimod 5% Cream	Massachusetts General Hospital	marketed	TLR7 agonist / Immune response modifier	TLR7 (Toll-like receptor 7)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (TLR7 agonist class)

Apotex Inc. · 1 drug in this class
Elion Therapeutics, Inc. · 1 drug in this class
Graceway Pharmaceuticals, LLC · 1 drug in this class
MEDA Pharma GmbH & Co. KG · 1 drug in this class
Medical University of Graz · 1 drug in this class
Medical University of Vienna · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). EL219 — Competitive Intelligence Brief. https://druglandscape.com/ci/el219. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab